Mark M. Pomerantz

The paper identifies epigenomic signatures in sarcomatoid renal cell carcinoma (sRCC) that predict response to immune checkpoint inhibitors and are detectable in plasma, enabling non-invasive diagnosis.

This study identifies multi-omics prognostic signatures for prostate cancer using transcriptomics and metabolomics data, showing their ability to stratify patients into distinct risk groups.

The paper introduces CWAS, a method linking genetic variation to chromatin states, identifying novel prostate cancer risk loci and regulatory mechanisms not detectable by eQTLs.

This study shows MYC overexpression disrupts AR transcriptional pause release, promoting aggressive prostate cancer progression.

PLASMA improves QTL fine-mapping by integrating allele-specific QTL information, achieving better resolution and smaller credible sets than existing methods.

The paper identifies allele-specific quantitative trait loci (asQTLs) in RCC, showing their enrichment in GWAS risk loci and linking them to hypoxia pathway interactions.